According to the company, the new, 225,000-square-foot expansion is a "crucial component" of a more than $12 billion infusion ...

At its sprawling complex in Durham, N.C., Merck has opened a new $1 billion, 225,000-square-foot manufacturing plant slated ...

With Merck & Co. largely propping up supplies of the bladder cancer-fighting bacteria Bacillus Calmette-Guérin (BCG) in the U.S., ImmunityBio has received the FDA all-clear to help pick up the ...

Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis live, attenuated culture preparation; 50mg per vial; pwd for intravesical administration after reconstitution and dilution ...

This program will provide patients in the U.S. with a critical alternative source of BCG, a standard-of-care treatment for bladder cancer. ImmunityBio said that Merck’s TICE BCG shortages have ...

while Merck & Co., based in New Jersey, currently is the only manufacturer of BCG (TICE® BCG) in the U.S. ImmunityBio has been awarded multiple patents covering the composition and methods of use ...

U.S. Urology Partners is one of the first providers to offer patients ImmunityBio’s recombinant Bacillus Calmette-Guérin (rBCG) The FDA recently authorized ImmunityBio’s EAP for rBCG to address U.S.

One of the significant industry players in the TICE BCG market is Merck And Co Inc. The main growth driver of the TICE BCG market is the rising incidence of bladder cancer. Bladder cancer ...

The development comes in response to significant supply shortages of Tice BCG [an attenuated, live culture preparation of the BCG strain of Mycobacterium bovis] which have been a major barrier to ...

while Merck & Co., based in New Jersey, currently is the only manufacturer of BCG (TICE ® BCG) in the U.S. ImmunityBio has been awarded multiple patents covering the composition and methods of ...

In a recent Sermo survey of 100 U.S. urologists, 57 percent indicated they were unable to treat patients in the last 12 months due to a lack of access to TICE ® BCG. The alternative BCG source ...